News
News from us and our partners
News
News
Biovelocita
News
Crossover
News
News
Industrial Biotech
News
Capital
News
Digital Medicine
News
Sofinnova Partners raises €1.2 billion to fuel the next wave of life sciences innovation
Sofinnova Partners exceeds target with €165M biotech acceleration fund, Europe’s largest, with strong Pharma support
CEO spotlight: Thierry Abribat's third straight win
Sofinnova’s newest partners discuss their career paths
Sofinnova publishes 2023 Impact Report
Johnson & Johnson to acquire Shockwave Medical
Cure51 raises €15 million to harness the power of cancer survivors
CEO spotlight: CinCor's Marc de Garidel
Tags
Topics
0 results
- News
BrightHeart obtains third FDA clearance and PCCP approval, becoming first to offer one integrated solution for real-time fetal heart documentation and CHD detection
- News
AAVantgarde presents positive clinical data from its AAVB-081 program for Usher 1B and preclinical data from its AAVB-039 program for Stargardt at the ARVO 2025 annual meeting
- News
HAYA Therapeutics raises $65 million in Series A funding to deliver precision RNA-guided medicines for chronic and age-related diseases
- News
Sitryx nominates SIT-047, a novel, oral MTHFD2 inhibitor, for clinical development in psoriatic arthritis
- News
Latent Labs and AWS announce collaboration to scale generative AI for the Life Sciences
- News
BrightHeart obtains second FDA clearance for expansion of platform capabilities - adding tablet support for fetal heart ultrasound evaluations
- News
SafeHeal® closes oversubscribed €35 million Series C equity financing
- News
NodThera’s oral NLRP3 inhibitor NT-0796 enhances and sustains weight loss in combination with GLP-1
- News
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis
- News
Rasmus Holm-Jorgensen appointed CFO at AAVantgarde
- News
Mainstay Medical announces exclusive coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
- News
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)
- News
CorWave announces successful completion of 6-month chronic in vivo study, paving the way for clinical trial initiation
- News
iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675
- News
ProQR strengthens leadership with appointments of CFO and CMO to support next phase of growth